Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 5/20 | 0.35 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 6/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18409196 | 0.89 | MAP4K1 (0.36) | JAK2JAK1TYK2JAK3ABL1 | |
| SCHEMBL18409197 | 0.88 | TYK2 (0.43) | JAK2JAK1TYK2JAK3ABL1 | |
| SCHEMBL18409435 | 0.82 | JAK2 (0.37) | JAK2JAK1TYK2JAK3ABL1 | |
| SCHEMBL18409455 | 0.80 | JAK2 (0.36) | JAK2JAK1TYK2JAK3ABL1 | |
| SCHEMBL18408927 | 0.79 | TYK2 (0.50) | JAK2JAK1TYK2JAK3ABL1 | |
| SCHEMBL18398366 | 0.76 | LMNA (0.36) | JAK2JAK1TYK2JAK3LMNA | |
| SCHEMBL18409262 | 0.75 | MAP4K1 (0.39) | ABL1LRRK2MAP4K1 | |
| SCHEMBL18409251 | 0.75 | MAP4K1 (0.39) | ABL1LRRK2MAP4K1 | |
| SCHEMBL18409443 | 0.73 | JAK2 (0.42) | JAK2JAK1TYK2JAK3ABL1 | |
| SCHEMBL18409370 | 0.73 | JAK2 (0.45) | JAK2JAK1TYK2JAK3ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017012647-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-01-26 | — | — | WO | disclosed |